<DOC>
	<DOCNO>NCT02471196</DOCNO>
	<brief_summary>This study evaluate effect ORM-12741 agitation/aggression symptom Alzheimer 's disease . Two third patient receive ORM-12741 one third receive placebo .</brief_summary>
	<brief_title>Efficacy ORM-12741 Agitation/Aggression Symptoms Alzheimer 's Disease</brief_title>
	<detailed_description>ORM-12741 potent selective alpha-2C adrenoceptor ( AR ) -antagonist . Previous result suggest compound may positive effect cognitive neuropsychiatric symptom Alzheimer 's Disease . In study , effect ORM-12741 evaluate agitation/aggression symptom neuropsychiatric symptom . Furthermore , cognition psychotic depressive symptom evaluate .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<criteria>Written inform consent ( IC ) participation study ( cosign subject 's next kin caregiver , legally acceptable representative . Written IC obtain consistently available caregiver informant knowledgeable subject 's condition progression willing accompany subject visit supervise administration study medication . Age 5590 year ( inclusive ) . Male female subject diagnosis probable Alzheimer 's Disease . Brain imaging ( compute tomography [ CT ] magnetic resonance image [ MRI ] ) consistent diagnosis Alzheimer 's Disease ( within 18 month screen ) . Minimental state examination ( MMSE ) score 1024 ( inclusive ) . Clinically significant agitation meeting International Psychogeriatric Association Provisional Criteria Agitation Cognitive Impairment . The agitation symptom need present least 4 week screen visit . Neuropsychiatric Inventory agitation/aggression item score least 4 screen visit . Modified Hachinski Ischemia Score ( MHIS ) &gt; 4 . Changes AChE inhibitor ( donepezil , rivastigmine galantamine ) dose within 2 month prior screen . Changes memantine dose within 2 month prior screen . Changes antidepressant dose addition another antidepressant medication within 2 month prior screen . Use antipsychotic dose within 1 month prior screen . Use benzodiazepine , shortacting sleep medication , night maximum 3 nights/week , within 2 month prior screen . Use anticholinergic medication within 2 month prior screen . Current use ( within 30 day prior screen ) medication know relevant alpha2C AR affinity ( e.g . mirtazapine , mianserin , clonidine , guanfacine tizanidine ) high noradrenaline transporter affinity ( reboxetine , venlafaxine duloxetine ) . Current use psychotropic agent , unless dose stable last 2 month prior screen . Myocardial infarction clinically significant ischemic cardiac disease , heart failure , arrhythmia tendency within past 2 year . Current history malignancy within 5 year screen . Suicidal ideation 6 month screen current suicide risk base ColombiaSuicide Severity Rating Scale ( CSSRS ) ( item 4 5 exclusionary ) current risk suicide base investigator 's judgement . Specific finding MRI CT could opinion investigator affect cognitive function ( cortical infarct silent lacuna region know affect cognition ) . Supine heart rate &lt; 48 bpm &gt; 100 bpm . Systolic blood pressure ( SBP ) &gt; 160 mmHg diastolic blood pressure ( DBP ) &gt; 100 mmHg 5minute rest . Symptomatic orthostatic hypotension . QTcFridericia ( QTcF ) repeatedly &gt; 450 m male &gt; 470 m female . Clinically significantly abnormal thyroidstimulating hormone ( TSH ) , vitamin B12 folate serum level screen . Resides skilled nursing facility .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>